HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers.

AbstractCONTEXT:
The nonpsychoactive cannabinoid, cannabidiol (CBD), has great potential for the treatment of chronic and 'breakthrough' pain that may occur in certain conditions like cancer. To fulfill this goal, suitable noninvasive drug delivery systems need to be developed for CBD. Chronic pain relief can be best achieved through the transdermal route, whereas 'breakthrough' pain can be best alleviated with intranasal (IN) delivery. Combining IN and transdermal delivery for CBD may serve to provide patient needs-driven treatment in the form of a nonaddictive nonopioid therapy.
OBJECTIVE:
Herein we have evaluated the IN and transdermal delivery of CBD with and without permeation enhancers.
MATERIALS AND METHODS:
In vivo studies in rats and guinea pigs were carried out to assess nasal and transdermal permeation, respectively.
RESULTS:
CBD was absorbed intranasally within 10 minutes with a bioavailability of 34-46%, except with 100% polyethylene glycol formulation in rats. Bioavailability did not improve with enhancers. The steady-state plasma concentration of CBD in guinea pigs after transdermal gel application was 6.3 +/- 2.1 ng/mL, which was attained at 15.5 +/- 11.7 hours. The achievement of a significant steady-state plasma concentration indicates that CBD is useful for chronic pain treatment through this route of administration. The steady-state concentration increased by 3.7-fold in the presence of enhancer. A good in vitro and in vivo correlation existed for transdermal studies.
CONCLUSION:
The results of this study indicated that CBD could be successfully delivered through the IN and transdermal routes.
AuthorsKalpana S Paudel, Dana C Hammell, Remigius U Agu, Satyanarayana Valiveti, Audra L Stinchcomb
JournalDrug development and industrial pharmacy (Drug Dev Ind Pharm) Vol. 36 Issue 9 Pg. 1088-97 (Sep 2010) ISSN: 1520-5762 [Electronic] England
PMID20545522 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Analgesics
  • Cannabinoids
  • Excipients
  • Cannabidiol
Topics
  • Absorption
  • Administration, Cutaneous
  • Administration, Intranasal
  • Analgesics (administration & dosage, blood, pharmacokinetics)
  • Animals
  • Area Under Curve
  • Biological Availability
  • Cannabidiol (administration & dosage, blood, pharmacokinetics)
  • Cannabinoids (administration & dosage, blood, pharmacokinetics)
  • Drug Compounding
  • Drug Delivery Systems
  • Excipients
  • Female
  • Guinea Pigs
  • Male
  • Permeability (drug effects)
  • Rats
  • Rats, Hairless
  • Skin

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: